BRAF gene mutation leads to different therapeutic responses in melanoma and colorectal cancer

A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the ...
Seeking Alpha

Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in disease ...
Managed Healthcare Executive

Limitations of Current Evidence for BRAF V600E-Mutant Metastatic NSCLC and Cross-Trial Comparisons

A final discussion point is real-world applicability. Although PHAROS presents exceptional PFS, the modest difference between ...
ascopubs.org

Using Artificial Intelligence to Support Informed Decision-Making on BRAF Mutation Testing

Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...
ascopubs.org

Melanoma 3.0T—Tech Innovations, New Targeted Therapies, and T-Cell Breakthroughs

New technologies and innovations are changing the future of melanoma care. Teledermatology and skin screening mobile apps aided by artificial intelligence (AI) diagnostic support could assist in ...
News Medical

Successful treatment of metastatic malignant glomus tumor with BRAF and MEK inhibitors

A new case report was published in Oncotarget's Volume 15 on October 11, 2024, entitled "Complete response to encorafenib plus binimetinib in a BRAF V600E-mutant metastasic malignant glomus tumor." As ...